Although many tumor markers have been identified and studied in epithelial ovarian cancer,a potential and useful screening marker for ovarian cancer has not been yet clearly established. Ovarian cancer is considered as a “silent killer”because of the absence of specific symptoms until late stage. Several validated biomarkers are currently used to diagnose and monitor the progression of the cancer,but very few of them show adequate specificity and sensitivity for different population screening. There is therefore an urge need to find biomarkers with high diagnostic accuracy and set up screening programs which can help detect ovarian cancer early,predict the response of the patient to anticancer therapy and guide physicians in choosing the best treatment for the patient. CA125,HE4 and STIP1 have been proven to play an important role as biomarkers in detecting and monitoring ovarian cancer. In this paper,we review evaluate,and highlight the role of CA125,HE4 and STIP1 in the detection of ovarian cancer.Potential biomarkers can help us distinguish malignancy from benign pelvic mass. Ovarian cancer has been considered as a “silent killer ” because of the absence of specific symptoms until Several validated biomarkers are currently used to diagnose and monitor the progression of the cancer, but very few of them show adequate specificity and sensitivity for different population screening. There is therefore an urgent need to find biomarkers with high diagnostic accuracy and set up screening programs which can help detect ovarian cancer early, predict the response of the patient to anticancer therapy and guide physicians in choosing the best treatment for the patient. CA125, HE4 and STIP1 have been proven to play an important role as biomarkers in detecting and monitoring ovarian cancer. In this paper, we review evaluate, and highlight the role of CA125, HE4 and STIP1 in the detection o f ovarian cancer. Potential biomarkers can help us distinguish malignancy from benign pelvic mass.